CD8A and neoplasm: The loss of TREX1 in tumor cells can initiate robust activation of both CD8+ T cells and NK cells, mitigate T cell exhaustion, and reprogram the immunosuppressive myeloid microenvironment, collectively enhancing the efficacy of immunotherapy (155).